Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Ginsenoside Rg1 as a Promising Adjuvant Agent for Enhancing the Anti-cancer Functions of Granulocytes Inhibited by Noradrenaline

PROVIDER: PRJNA929088 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23263612_1.fastq.gz	Fastqsanger.gz
	SRR23263612_2.fastq.gz	Fastqsanger.gz
	SRR23263613_1.fastq.gz	Fastqsanger.gz
	SRR23263613_2.fastq.gz	Fastqsanger.gz
	SRR23263614_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Project description:Ginsenoside Rg1

| PRJNA726376 | ENA

Expression data from MCF-7 breast cancer cells treated with CNTs, ginsenosides (Rb1 and Rg1) and conjugates (Rb-CNTs and Rg-CNTs)

Project description:To investigate the effects of ginsenosides-CNTs conjugtaes on total expression profile of MCF-7 breast cancer cells, we conjugated ginsenoides Rb1 and Rg1 with multi-walled carbon nanotubes in a 5:1 ratio. Objectives for this study included the identification of genes that were up or down-regulated at the transcriptional level in MCF-7 cells treated with ginsenoside-CNTs conjugates and compare it to the ginsenosides alone (Rb1 and Rg1)

2016-12-15 | GSE75570 | GEO

Role of MicroRNA-214 in Ginsenoside-Rg1-induced Angiogenesis

Project description:MicroRNAs (miRNAs) are small non-coding RNAs that act as post-transcriptional gene modulators. Ginsenoside-Rg1, one of the active components of ginseng, has been confirmed by us as an angiogenesis inducer. Using miRNA microarray analysis, a total of 15 (including miR-214) and 3 miRNAs were found to be down- or up-regulated by Rg1 in human umbilical vein endothelial cells (HUVEC), respectively. Since miR-214 is closely related to endothelial nitric oxide synthase (eNOS) and hence angiogenesis; its expression was further validated by qRT-PCR. We also investigated the role of miR-214 on eNOS expression and in tubulogenesis of HUVEC by transfection of specific miRNA inhibitor or precursor. Our results suggested that Rg1 can down-regulate miR-214 expression in HUVEC, leading to an increase in eNOS expression which can promote angiogenesis. This result signifies a new understanding towards how a simple natural compound can affect physiological changes through modulation of miRNA expression. The study is used to investigate the role of miRNA-214 in Rg1-induced human endothelial cells.

2010-08-05 | E-GEOD-17541 | biostudies-arrayexpress

Role of MicroRNA-214 in Ginsenoside-Rg1-induced Angiogenesis

2010-08-05 | GSE17541 | GEO

A systematic exploration on Ginsenoside Rg5 reveals proresolving functions in airway mucous cells.

Project description:Ginsenoside Rg5 reveals proresolving functions in airway mucous cells through inhibition of ROS production and promoting anti-inflammation factors

2023-01-25 | GSE173990 | GEO

Ginsenoside compound K plays an anti-inflammatory effect without inducing glucose metabolism disorder in adjuvant-induced arthritis rats

Project description:We studied hepatic mRNA expression levels in normal Wistar rats, adjuvant arthritic (AA) rats, and AA rats administered by gavage (ginsenoside CK or dexamethasone). The aim of the study was to determine the differences in the effects of ginsenoside CK and dexamethasone on hepatic mRNA levels in AA rats. The dexamethasone group may have a greater effect on mRNA in the liver.

2025-03-07 | GSE261056 | GEO

Evaluation of pharmacological effects of ginsenoside Rk2 on hepatic ischemia/reperfusion-injury in vivo and in vitro [HuH7]

Project description:Hepatic ischemia-reperfusion injury (IRI) poses a significant concern in conditions such as hemorrhagic shock, hepatic resection, and liver transplantation. Recent studies have highlighted the potential of phytomedicines and natural products in effectively protecting against various forms of IRIs. In this particular investigation, we conducted high-throughput screening and identified ginsenoside Rk2 (RK), a rare dehydroprotopanaxadiol saponin, as a promising agent for hepatic IRI. Our subsequent in vivo and in vitro studies demonstrated that Rk2 effectively mitigated inflammation and apoptosis induced by hepatic IRI in a dose-dependent manner. In this study, we comprehensively investigate the pharmacological effects of ginsenoside Rk2 in the treatment of hepatic IRI and elucidate potential molecular mechanisms in vitro.

2024-12-20 | GSE284059 | GEO

Evaluation of pharmacological effects of ginsenoside Rk2 on hepatic ischemia/reperfusion-injury in vivo and in vitro [mouse]

Project description:Hepatic ischemia-reperfusion injury (IRI) poses a significant concern in conditions such as hemorrhagic shock, hepatic resection, and liver transplantation. Recent studies have highlighted the potential of phytomedicines and natural products in effectively protecting against various forms of IRIs. In this particular investigation, we conducted high-throughput screening and identified ginsenoside Rk2 (Rk2), a rare dehydroprotopanaxadiol saponin, as a promising agent for hepatic IRI. Our subsequent in vivo and in vitro studies demonstrated that Rk2 effectively mitigated inflammation and apoptosis induced by hepatic IRI in a dose-dependent manner. In this study, we comprehensively investigate the pharmacological effects of ginsenoside Rk2 in the treatment of hepatic IRI and elucidate potential molecular mechanisms in vivo.

2024-12-20 | GSE284060 | GEO

Homo sapiens

Project description:Role of MicroRNA-214 in Ginsenoside-Rg1-induced Angiogenesis

| PRJNA118533 | ENA

Proteoglycan 4 and regorafenib synergistically reduce HCC progression in an orthotopic model

Project description:Background: Hepatocellular carcinoma (HCC) is a major therapeutic challenge, with limited long-term benefits from treatments such as regorafenib due to their efficacy and adverse effects. Proteoglycan-4 (PRG4) has previously shown promise in enhancing anti-proliferative effects of multi-kinase inhibitors in simple in vitro two-dimensional (2D) HCC models. Objective: We evaluated the adjuvant effect of PRG4 in enhancing regorafenib’s anti-tumor efficacy in preclinical more complex in vitro three-dimensional (3D) HCC tumoroids, and in vivo HCC models. Design: HLC19 and HLF HCC cell lines were engineered to stably overexpress PRG4. Anti-proliferative effects of PRG4, either alone or in combination with regorafenib, were evaluated in 2D monolayers, 3D Matrigel embedded spheroids and orthotopic xenograft mouse models established via HCC cells intrahepatic injection. RNA sequencing was done to assess the transcriptomic profiles of PRG4 overexpressing spheroids. Results: PRG4 expression partially inhibited HCC tumor growth in vivo, but enhanced regorafenib treatment leading to a near-complete tumor regression. PRG4 expression significantly impaired cell growth in both 2D and 3D HCC models in vitro. In an angiogenesis in vitro model, PRG4 hindered endothelial tubulogenesis both alone and in combination with regorafenib. By transcriptomic analysis of matrigel-embedded HCC cell spheroids exposed to PRG4 and/or regorafenib, PDGF pathway emerged as a target of PRG4 + regorafenib, corroborating the role of PRG4 in impairing angiogenesis. G0/G1 phase of cell cycle resulted more delayed in spheroids exposed to PRG4 and regorafenib than those treated with regorafenib only, compared to untreated cells. Conclusions: PRG4 enhances the anti-tumor activity of regorafenib across various HCC models. These findings support PRG4 as a promising adjuvant candidate to improve clinical outcomes in HCC.

2026-01-14 | GSE299840 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data